

Urteste S.A.  
Starodworska  
180-137 Gdańsk

11 October 2024

**Current report number 10/2024  
of 11.10.2024**

**Subject:** Conclusion of an agreement with Avania for the preparation of documentation for the conduct of a clinical trial in the PANURI project

**Legal basis:** Article 17(1) of MAR - inside information.

The Management Board of Urteste S.A. (the "Issuer", "the Company") announces that on October 11, 2024, the Company entered into an agreement with Avania BV, headquartered in the Netherlands. The agreement covers the preparation of documents and a comprehensive review of the content and regulatory requirements necessary to conduct a clinical trial for an in vitro diagnostic test aimed at detecting pancreatic cancer (the PANURI project).

This agreement marks a key step in the Company's preparations for the clinical trial, which is intended to facilitate the certification and registration process of the in vitro diagnostic medical device in the USA, UK, and EU markets.

Avania is the leading global MedTech clinical research organization (CRO) and an advisory partner with focused on medical devices, diagnostics/IVDs, and digital health. Core offerings include full-service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services.

The Company plans to start the clinical trial for the PANURI project in the first quarter of 2025.